Focal experimental autoimmune encephalomyelitis in the Lewis rat induced by immunization with myelin oligodendrocyte glycoprotein and intraspinal injection of vascular endothelial growth factor

GLIA

Volumn 58, Issue 13, 2010, Pages 1523-1531

  Sasaki, Masanori ^a,b   Lankford, Karen L ^a,b   Brown, Robert J ^a,b   Ruddle, Nancy H ^a   Kocsis, Jeffery D ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Demyelination; EAE; Spinal cord; VEGF

Indexed keywords

FREUND ADJUVANT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; T LYMPHOCYTE ANTIBODY; VASCULOTROPIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATING DISEASE; DEMYELINATION; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNIZATION; INFLAMMATION; INJECTION SITE; LEWIS RAT; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; SPINAL CORD; SYSTEMIC DISEASE; T LYMPHOCYTE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; ANTIGENS, CD3; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FREUND'S ADJUVANT; INJECTIONS, SPINAL; LIPIDS; MICROSCOPY, ELECTRON, TRANSMISSION; MYELIN-ASSOCIATED GLYCOPROTEIN; RATS; RATS, INBRED LEW; SPINAL CORD; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957350262     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21026     Document Type: Article

References (31)

1. Benton RL, Whittemore SR. 2003. VEGF165 therapy exacerbates secondary damage following spinal cord injury. Neurochem Res 28:1693-1703. (Pubitemid 37296211)
2. Blakemore WF. 1984. The response of oligodendrocytes to chemical injury. Acta Neurol Scand Suppl 100:33-38.
3. Blakemore WF, Patterson RC. 1978. Suppression of remyelination in the CNS by X-irradiation. Acta Neuropathol 42:105-113.
4. Bright JJ. 2007. Curcumin and autoimmune disease. Adv Exp Med Biol 595:425-451.
5. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439.
6. Carvalho JF, Blank M, Shoenfeld Y. 2007. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol 27:246-256. (Pubitemid 46790822)
7. Choi JS, Kim HY, Cha JH, Choi JY, Park SI, Jeong CH, Jeun SS, Lee MY. 2007. Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 following acute spinal cord contusion in rats. J Histochem Cytochem 55:821-830.
8. Dobrogowska DH, Lossinsky AS, Tarnawski M, Vorbrodt AW. 1998. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. J Neurocytol 27:163-173. (Pubitemid 28253067)
9. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'shea KS, Powell-Braxton L, Hillan K, Moore MW. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442.
10. Gold R, Linington C, Lassmann H. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129(Pt 8):1953-1971. (Pubitemid 44289062)
11. Kamada H, Yu F, Nito C, Chan PH. 2007. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: Relation to blood-brain barrier dysfunction. Stroke 38:1044-1049. (Pubitemid 46568472)
12. Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, Kingsley DP, Moseley IF, du Boulay EP, McDonald WI. 1990. Heterogeneity of blood-brain barrier changes in multiple sclerosis: An MRI study with gadolinium-DTPA enhancement. Neurology 40:229-235.
13. Kerschensteiner M, Stadelmann C, Buddeberg BS, Merkler D, Bareyre FM, Anthony DC, Linington C, Brück W, Schwab ME. 2004. Targeting experimental autoimmune encephalomyelitis lesions to a predetermined axonal tract system allows for refined behavioral testing in an animal model of multiple sclerosis. Am J Pathol 164:1455-1469.
14. Lankford KL, Imaizumi T, Honmou O, Kocsis JD. 2002. A quantitative morphometric analysis of rat spinal cord remyelination following transplantation of allogenic Schwann cells. J Comp Neurol 443:259-274. (Pubitemid 34093465)
15. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. 1988. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130:443-454. (Pubitemid 18091372)
16. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. 2007. Lesion genesis in a subset of patients with multiple sclerosis: A role for innate immunity? Brain 130(Pt 11):2800-2815.
17. Marta CB, Bansal R, Pfeiffer SE. 2008. Microglial Fc receptors mediate physiological changes resulting from antibody cross-linking of myelin oligodendrocyte glycoprotein. J Neuroimmunol 196:35-40.
18. Merkler D, Ernsting T, Kerschensteiner M, Bruck W, Stadelmann C. 2006. A novel focal EAE model of cortical demyelination: Multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 129:1972-1983.
19. Miller DH, Rudge P, Johnson G, Kendall BE, Macmanus DG, Moseley IF, Barnes D, McDonald WI. 1988. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 111 (Pt 4):927-939.
20. Minagar A, Alexander JS. 2003. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 9:540-549. (Pubitemid 37479401)
21. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. 2000. Multiple sclerosis. N Engl J Med 343:938-952.
22. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, Galli R, Del Carro U, Amadio S, Bergami A, et al. 2003. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422:688-694.
23. Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ. 2002. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 61:914-925.
24. Roscoe WA, Welsh ME, Carter DE, Karlik SJ. 2009. VEGF and angiogenesis in acute and chronic MOG (35-55) peptide induced EAE. J Neuroimmunol 209:6-15.
25. Saab CY, Craner MJ, Kataoka Y, Waxman SG. 2004. Abnormal Purkinje cell activity in vivo in experimental allergic encephalomyelitis. Exp Brain Res 158:1-8. (Pubitemid 39208518)
26. Sasaki M, Black JA, Lankford KL, Tokuno HA, Waxman SG, Kocsis JD. 2006. Molecular reconstruction of nodes of Ranvier after remyelination by transplanted olfactory ensheathing cells in the demyelinated spinal cord. J Neurosci 26:1803-1812.
27. Sasaki M, Radtke C, Tan AM, Zhao P, Hamada H, Houkin K, Honmou O, Kocsis JD. 2009. BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. J Neurosci 29:14932-14941.
28. Sköld M, Cullheim S, Hammarberg H, Piehl F, Suneson A, Lake S, Sjögren A, Walum E, Risling M. 2000. Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration. Eur J Neurosci 12:3675-3686.
29. Theoharides TC, Konstantinidou AD. 2007. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 12:1615-1628.
30. Toyama K, Honmou O, Harada K, Suzuki J, Houkin K, Hamada H, Kocsis JD. 2009. Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. Exp Neurol 216:47-55.
31. Westland KW, Pollard JD, Sander S, Bonner JG, Linington C, McLeod JG. 1999. Activated non-neural specific T cells open the blood-brain barrier to circulating antibodies. Brain 122 (Pt 7):1283-1291. (Pubitemid 29324849)